SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a Seattle, Wash.-based gene therapy company, announced today it is a winner of the Most Promising Company Award from the Precision Medicine World Conference, held in Silicon Valley last week. The award recognizes companies with especially promising and innovative health care diagnostic, therapeutic and technological solutions.
Sean Ainsworth hopes to strike biotech gold, again, joining Seattle-based Immusoft Corp. as CEO and chairman. Immusoft is a gene-therapy company that hopes to use a patient’s immune cells to treat diseases, including MPS-I, or mucopolysaccharidosis type I, a rare genetic disease that is expected to be Immusoft’s first clinical application. The company uses a cell-culture system invented by Nobel laureate David Baltimore that it calls Immune System Programming.
Immusoft is looking to get its gene therapy technology into clinical trials, and the Seattle startup announced Friday that it has raised $3 million to kickstart that process. The funding is first part of the company’s ongoing Series B…. Veteran biotech executive Sean Ainsworth is joining the company as its new CEO, filling the shoes of the company’s Founder and longtime CEO Matthew Scholz. Scholz is transitioning to become the company’s CTO and will retain his position on the board of directors.
SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a Seattle, Wash.-based gene therapy company, announced today it has closed a $3M initial tranche of a Series B financing. The full Series B is underway. The round is expected to provide Immusoft the funding it needs to complete its Phase I/II clinical trial in MPS-I (Mucopolysaccharidoses type I) and advance its pipeline, which uses its proprietary Immune System Programming (ISP™) approach to B cell modification for treating diseases.
Immusoft has closed $2.7 million in Series A3 funding. The Seattle-based gene therapy startup developed technology that uses a patient’s immune cells to cure disease. It will use the funding to prepare for a new drug trial with the Food and Drug Administration.“The capital raised in this round will give us the resources we need to submit our Investigational New Drug application,” founder and CEO Matthew Scholz said in a news release. “We are grateful to our investors and for the speed in which we were able to close our latest effort to raise capital.”
SEATTLE, Wash. (November 1, 2016)— Immusoft Corporation, a Seattle, Wash.-based gene therapy company, has closed on $2.74 million of a $3 million fundraising round. Founders Fund’s FF Science and Technium Partners led the investment. The round was oversubscribed and Immusoft says it expects to close on the remaining amount shortly.
On March 8, one of the first companies we funded, Immusoft, announced it has acquired Discovery Genomics, Inc., bringing new expertise and technologies to its therapeutic platform. We asked Matthew Scholz, CEO, if he could share the story behind the acquisition and what it means for Immusoft going forward.
A Seattle biotech is working on technology that resembles the plot of Jurassic Park. Immusoft just acquired Minneapolis-based Discovery Genomics, a company that makes it possible for researchers to cut and paste DNA. The technology is called the Sleeping Beauty Transposon System. It gets its name from the process used to create it. … “In effect, they woke it up from an evolutionary sleep, which is how the name Sleeping Beauty became applied to it,” Immusoft CEO Matthew Scholz said. … Rather than making dinosaurs on a private island, though, Immusoft plans to make treatments for genetic diseases.
Immusoft, a Seattle-based biotech startup that has developed a way to manipulate human immune cells, today announced the acquisition of Discovery Genomics, a 16-year-old company based in Minneapolis, Minn. … Immusoft CEO Matthew Scholz said that his company acquired Discovery Genomics to gain its scientific expertise and key technology called the Sleeping Beauty Transposon System, which is used to deliver genes into cells to prevent or alleviate a disease state, all without using a virus. “Our two companies share a culture of innovation and a desire to change the way many diseases can be treated,” Scholz said in a statement. “It is my hope and expectation that combining our expertise and technology will help us in this pursuit.”
Immusoft has acquired Discovery Genomics…in a deal that expands the buyer’s technology holdings. With the acquisition, Immusoft has added to its portfolio Discovery Genomics’ Sleeping Beauty Transposon™ System, designed to deliver genes into cells using DNA rather than a virus. Immusoft said it plans to use the Sleeping Beauty Transposon System with its Immune System Programming (ISP™) technology platform. … Founded in 2000 and operational 2 years later, Discovery Genomics is based in Minneapolis. The company’s founders include Perry Hackett, Ph.D., whose lab invented the Sleeping Beauty Transposon System.
SEATTLE & MINNEAPOLIS–(BUSINESS WIRE)–Immusoft Corporation, a Seattle, Wash.-based gene therapy company, announced today it has purchased Minneapolis, Minn.-based Discovery Genomics, Inc. The acquisition brings to Immusoft renowned scientific expertise and key technology, the Sleeping Beauty Transposon System, which Discovery Genomics uses to deliver genes into cells without using a virus.
What’s less well known about Thiel is his affinity for biotechnology. … He has invested in more than 25 startups…. Immusoft … is using gene therapy to turn blood cells into drug factories …. Matthew Scholz, a software entrepreneur, says he became obsessed with the idea that the immune system can be “programmed.” … The Breakout grant allowed him to demonstrate his ideas in mice for the first time.
For centuries, explorers have searched the world for the fountain of youth. Today’s billionaires believe they can create it, using technology and data.
MPS I is a rare genetic disease that is incurable and lethal by age 12. Seattle-based Immusoft thinks it can harness a key part of the immune system to manufacture a missing enzyme needed to treat the disease. It represents a broader effort on the part of the company to develop a platform to treat a wide range of disease by turning immune system cells into drug factories.
The future of pharma is to learn to address the human body as an information platform. A company in Seattle named Immusoft, partly financed by venture investor Peter Thiel, has been successfully pursuing this strategy and proven its feasibility with mice, using viruses and other vectors to program immune cells to emit needed molecules.
In 2008, Thiel made Founders Fund’s first substantial biotech investment…. Matthew Scholz … recruited biologists and bootstrapped Immusoft, which “programs” B cells–types of white blood cells that produce antibodies–to generate their own medicine. … Instead of injecting treatments into a patient, cells are extracted, rewired to produce a treatment, and then returned to the body. … [L]ong-lasting DNA therapies like Immusoft’s could become a giant thorn for pharma companies whose profits depend on eternal prescription refills. “Once we treat all their patients, they’re done,” says Scholz.
Biotech seeking approval for clinical trial to treat MPS I
Seattle biotech startup Immusoft Corp. has raised $2.37 million from investors, including FF Science, a San Francisco venture fund that targets early stage technology and science companies. Founder and CEO Matthew Scholz, who launched Immusoft in 2009, said the funding will allow his company to scale up research, including approaching the U.S. Food and Drug Administration about doing human clinical trials…
Immunological memory, as provided by antibodies, depends on the continued presence of antibody-secreting cells, such as long-lived plasma cells of the bone marrow. Survival niches for these memory plasma cells are limited in number. In an established immune system, acquisition of new plasma cells, generated in response to recent pathogenic challenges, requires elimination of old memory plasma cells. Here, we review the adaptation of plasma cell memory to new pathogens…
“It struck me that the way the body attacks a pathogen is similar to the way a computer attacks a password,” Scholz said. “You have this idea of immunity memory. If you get a vaccine, your body remembers it and suddenly the disease that used to kill you won’t even give you the sniffles. … So we really set about treating disease from an information-based perspective.”
Imagine never having to take a pill again. Instead, mini drug factories hidden inside your bones, and made from your own immune cells, would churn out personalised drugs and other molecules designed to keep you fit and healthy. Such a factory has been created in mice, and could soon be tested in humans to treat HIV. “We want to turn people’s cells into drug factories, giving them the genetic information they need to produce their own treatment,” says Matthew Scholz of Immusoft in Seattle, which is developing the technique…
Matthew Scholz has been told many times that his idea for reprogramming the body’s immune cells to create drugs was impossible. Maybe dangerous. Maybe just dumb. Scholz, a computer scientist with no formal biology training, could easily have been written off as a quixotic dreamer until this spring, when he got his breakout moment. The foundation started by Peter Thiel, the billionaire co-founder of PayPal, decided that Scholz’s startup,Immusoft, just might be onto something, granting it close to $400,000…
Peter Thiel, an early venture investor in Facebook and FierceMarkets, has handed out a round of grants of up to $350,000 to a slate of 6 startup biotech companies, each of which promises a game-changing approach to medicine. And he’s hoping that handing out checks to these startup dreamers will help ignite some radical thinking on the possibilities of our collective “amazing future.”…
While most of us are still reeling in shock after last week’s one billion Instagram buy, Peter Thiel — through both Founders Fund and the Thiel Foundation — is leading the charge into a future where humans don’t age or suffer from cancer, among other things. Call it crazy or whatever you’d like, but there’s no doubt that people who are trying to drastically change the world for the better often do…
Although the concept of cell programming isn’t new, Immusoft Corp.’s approach represents a new spin on the science. For a biotech company, Seattle-based Immusoft started with a decidedly different pedigree. With a background in computer sciences rather than chemistry or biology, Matthew Scholz, the company’s founder and CEO, conceived an idea to fight disease by modifying information in human immune cells…